Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed advanced measurable or evaluable solid tumors unresponsive to currently available therapies, or for which there is no curative therapy
Eastern Cooperative Oncology Group (ECOG) performance status 0 and 1
Life expectancy more than12 weeks
Adequate bone marrow, liver and renal function
You may not be if
Known brain metastasis
Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of start of screening procedures
Major surgical procedure within 4 weeks of start of screening procedures
Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months
Clareo Health | A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
